# **UBE1** [6His-tagged]

E1 - Ubiquitin Activating Enzyme

Alternate Names: A1S9, A1S9T, BN75 temperature sensitivity complementing, A1ST, CTD-2522E6.1, GXP1, MGC4781, tsA1S9, UBE1X, Ubiquitin-activating enzyme E1

**Cat. No. 61-0001-010** Quantity: 10 μg **Lot. No.** 30135 Storage: -70°C

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS



**CERTIFICATE OF ANALYSIS Page 1 of 2** 

Protein Sequence: Please see page 2

## **Background**

The enzymes of the ubiquitylation pathway play a pivotal role in a number of cellular processes including regulated and targeted proteasomal degradation of substrate proteins. Three classes of enzymes are involved in the process of ubiquitylation; activating enzymes (E1s), conjugating enzymes (E2s) and protein ligases (E3s). UBE1 is a member of the E1 activating enzyme family and cloning of the human gene was first described by Handley et al. (1991). The UBE1 gene has been mapped to Xp11.3-p11.23 by highresolution fluorescence in situ hybridization (Takahashi et al., 1992). UBE1 'activates' ubiquitin through catalysing a C-terminal ATP dependent adenylation of the protein which results in it forming a high-energy thioester bond with the sulfhydryl group of UBE1. UBE1 is monomeric and there are two active sites within the UBE1 protein allowing it to bind two ubiquitin moieties at a time, with a new ubiquitin forming an adenylate intermediate as the previous one is transferred to the thiol site (Jin et al., 2007; Zheng et al., 2009). Defects in UBE1 are known to cause spinal muscular atrophy Xlinked type 2 (SMAX2) also known as X-linked lethal infantile spinal muscular atrophy, distal X-linked arthrogryposis multiplex congenita or X-linked arthrogryposis type 1 (AMCX1). Spinal muscular atrophy refers to a group of neuromuscular disorders charac

Continued on page 2

## **Physical Characteristics**

Species: human

Source: Sf21 insect cell-baculovirus ex-

pression

Quantity: 10 µg

Concentration: 0.5 mg/ml

**Formulation:** 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~121 kDa

Purity: >98% by InstantBlue™ SDS-PAGE


Stability/Storage: 12 months at -70°C;

aliquot as required

## Quality Assurance

## **Purity:**

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 µg His-UBE1



## Protein Identification:

Confirmed by mass spectrometry.

#### E1-Ubiquitin Thioester Loading Assay:

The activity of His-UBE1 was validated by loading ubiquitin onto the active cysteine of His-UBE1. Incubation of the His-UBE1 enzyme in the presence of ubiquitin and ATP at  $30^{\circ}$ C was compared at two time points,  $T_0$  and  $T_{10}$  minutes. Sensitivity of the ubiquitin/His-UBE1 thioester bond to the reducing agent DTT was confirmed.



Dundee, Scotland, UK

#### **ORDERS / SALES SUPPORT**

**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233) **International:** +1-617-245-0003

Email: sales.support@ubiquigent.com

#### **UK HQ and TECHNICAL SUPPORT**

International: +1-617-245-0020
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© **Ubiquigent 2011**. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

## **UBE1** [6His-tagged]

E1 - Ubiquitin Activating Enzyme

Alternate Names: A1S9, A1S9T, BN75 temperature sensitivity complementing, A1ST, CTD-2522E6.1, GXP1, MGC4781, tsA1S9, UBE1X, Ubiquitin-activating enzyme E1

**Cat. No. 61-0001-010** Quantity: 10 μg **Lot. No. 30135** Storage: -70°C

FOR RESEARCH USE ONLY NOT FOR USE IN HUMANS



**CERTIFICATE OF ANALYSIS Page 2 of 2** 

### **Background**

Continued from page 1

terized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMAX2 is a lethal infantile form presenting with hypotonia, areflexia, and multiple congenital contractures (Ramser *et al.*, 2008).

#### References:

Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL (1991) Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. *Proc Natl Acad Sci USA* **88**, 258-62.

Jin J, Li X, Gygi SP, Harper JW (2007) Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. *Nature* **447**, 1135-8.

Ramser J, Ahearn ME, Lenski C, Yariz KO, Hellebrand H, von Rhein M, Clark RD, Schmutzler RK, Lichtner P, Hoffman EP, Meindl A, Baumbach-Reardon L. (2008) Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. *Am J Hum Genet* **82**, 188-93.

Takahashi E, Ayusawa D, Kaneda S, Itoh Y, Seno T, Hori T (1992) The human ubiquitin-activating enzyme E1 gene (UBE1) mapped to band Xp11.3----p11.23 by fluorescence in situ hybridization. *Cytogenet Cell Genet* **59**, 268-9.

Zheng M, Liu J, Yang Z, Gu X, Li F, Lou T, Ji C, Mao Y (2009) Expression, purification and characterization of human ubiquit-in-activating enzyme, UBE1. *Mol Biol Rep* **37**, 1413-9.

## **Physical Characteristics**

Continued from page 1

#### **Protein Sequence:**

M S Y Y H H H H H H D Y D I P T T E N L YFQGAMGS SSPLSKKRRVSGPDPKPGSNC SPAQSVLSEVPSVPTNGMAKNGSEADIDE GLYSRQLYVLGHEAMKRLQTSSVLVS GLRGLGVEIAKNIILGGVKAVTLHDQG TAQWADLSSQFYLREEDIGKNRAEVSQPR LAELNSYVPVTAYTGPLVEDFLSGFQV VVLTNTPLEDQLRVGEFCHNRGIKLV VADTRGLFGQLFCDFGEEMILTDSNGEQ PLSAMVSMVTKDNPGVVTCLDEARHGFES GDFVSFSEVQGMVELNGNQPMEIKVLG PYTFSICDTSNFSDYIRGGIVSQVKVPKK ISFKSLVASLAEPDFVVTDFAKFSRPAOL HIGFQALHQFCAQHGRPPRPRNEEDAAEL VALAQAVNARALPAVQQNNLDED LIRKLAYVAAGDLAPINAFIGGLAAQEVM KACSGKFMPIMOWLYFDALECLPEDKEV LTEDKCLORONRYDGOVAVFGSDLOEKL GKQKYFLVGAGAIGCELLKNFAMIGL GCGEGGEIIVTDMDTIEKSNLNRQFL FRPWDVTKLKSDTAAAAVRQMNPHIRVT SHQNRVGPDTERIYDDDFFQNLDG VANALDNVDARMYMDRRCVYYRKPLLES GTLGTKGNVQVVIPFLTESYSSSQDP PEKSIPICTLKNFPNAIEHTLQWARDE FEGLFKQPAENVNQYLTDPKFVERTLR LAGTQPLEVLEAVQRSLVLQRPQTWAD CVTWACHHWHTQYSNNIRQLLHNFPP DQLTSSGAPFWSGPKRCPHPLTFDVNNPL HLDYVMAAANLFAQTYGLTGSQDRAAVAT FLOSVOVPEFTPKSGVKIHVSDOELOSAN ASVDDSRLEELKATLPSPDKLPGFKMYP IDFEKDDDSNFHMDFIVAASNLRAENY DIPSADRHKSKLIAGKIIPAIATTTAAV VGLVCLELYKVVQGHRQLDSYKNGFLN LALPFFGFSEPLAAPRHQYYNQEWTLW DRFEVQGLQPNGEEMTLKQFLDYFKTE HKLEITMLSQGVSMLYSFFMPAAKLK ERLDQPMTEIVSRVSKRKLGRHVRALV LELCCNDESGEDVEVPYVRYTIR

Tag (bold text): N-terminal His

Protease cleavage site: TEV (<u>ENLYFQ▼G</u>)

UBE1 (regular text): Start bold italics (amino acid residues

Accession number: NP\_003325



Dundee, Scotland, UK

#### **ORDERS / SALES SUPPORT**

US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) International: +1-617-245-0003

Email: sales.support@ubiquigent.com

#### UK HQ and TECHNICAL SUPPORT

International: +1-617-245-0020

Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0